N

NewAmsterdam Pharma Company NV
D

NAMS

18.550
USD
-0.42
(-2.21%)
مغلق
حجم التداول
21,460
الربح لكل سهم
-2
العائد الربحي
-
P/E
-8
حجم السوق
1,985,837,212
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: NewAmsterdam Pharma Company NV

القطاع: Healthcare
الصناعة: Biotechnology
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.